Jainex Aamcol Limited has filed its quarterly compliance statement with BSE Limited, confirming no deviation or variation in the utilization of funds raised through its right issue of equity shares for the quarter ended December 31, 2025. The statement was submitted on February 13, 2026, in compliance with Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Right Issue Details

The company successfully raised ₹897.80 lakhs through its right issue with the date of allotment being December 10, 2025. CARE Ratings Limited serves as the monitoring agency for the fund utilization, ensuring proper deployment of the raised capital.

Fund Allocation and Utilization

The board of directors revised the cost allocation for each object through a resolution dated December 10, 2025. The revised allocation demonstrates strategic financial management, particularly in debt repayment priorities.

Strategic Debt Management

The management prioritized the repayment of unsecured loans over secured loans due to higher interest costs associated with unsecured borrowings. The company reduced allocation for secured loan repayment by ₹192.00 lakhs and redistributed these funds across other objects, particularly increasing the allocation for unsecured loan repayment by ₹148.02 lakhs.

Audit Committee Oversight

The Audit Committee reviewed the fund utilization and allocation changes, taking management's explanation on record. The committee concluded that the strategic reallocation of funds does not constitute a deviation or variation in the use of funds raised through the right issue, as the changes were made within the management's discretion as per the offer document.

Compliance and Monitoring

The quarterly statement confirms that the utilization of proceeds during Q3FY26 aligns with the revised allocation approved by the board. Both the Audit Committee and auditors provided nil comments, indicating satisfactory compliance with regulatory requirements and proper fund deployment according to stated objectives.

Jainex aamcol Limited has formally notified the Bombay Stock Exchange about an upcoming board meeting scheduled to discuss its quarterly financial performance. The announcement, made on February 5, 2026, outlines the company's compliance with regulatory disclosure requirements.

Board Meeting Details

The board of directors will convene on February 13, 2026, at the company's registered office located at L-3 MIDC Industrial Area, P.O. Chikalthana, Aurangabad – 431006. The primary agenda focuses on reviewing the company's financial performance for the recent quarter.

Financial Results Review

The board will consider and approve the unaudited financial results for two specific periods:

• Quarter ended December 31, 2025
• Nine months ended December 31, 2025

This review represents the company's Q3FY26 performance assessment, providing stakeholders with insights into the operational and financial developments during this period.

Trading Window Restrictions

In accordance with regulatory compliance, Jainex Aamcol Limited has implemented a trading window closure affecting multiple stakeholder categories. The restriction period spans from January 1, 2026, to February 15, 2026.

The company has formally communicated these restrictions to all relevant parties, ensuring compliance with insider trading regulations during the financial results preparation and announcement period.

Regulatory Compliance

The announcement fulfills the requirements under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed companies to inform stock exchanges about board meetings where financial results will be considered, ensuring transparency and proper market disclosure.

The communication was signed by Kunal Bafna, Whole-time Director and CFO (DIN: 00902536), demonstrating proper authorization and corporate governance practices in the disclosure process.